Youmeishafen hydrobromide tablet of Zhongsheng Pharmaceutical Co., Ltd. is the first one in China!

Today, Zhongsheng pharmaceutical announced that South China pharmaceutical, a wholly-owned subsidiary of the company, has recently received the approval document for supplementary drug application approved and issued by the State Food and Drug Administration with the approval number of 2019b04697 According to the pharmaceutical intelligence data, no other enterprises in China have applied for the conformity assessment of generic quality and efficacy of Dextromethorphan Hydrobromide South China pharmaceutical industry is the only enterprise in China that has applied for the conformity assessment of generic quality and efficacy of Dextromethorphan Hydrobromide tablets Dextromethorphan Hydrobromide tablet is an over-the-counter antitussive drug, which belongs to class a over-the-counter drug It is suitable for dry cough, including cough caused by upper respiratory tract infection (such as cold and pharyngitis), bronchitis, etc Dextromethorphan Hydrobromide is a kind of central antitussive drug, which can inhibit the cough center and produce antitussive effect Its antitussive effect is equal to or slightly stronger than codeine General treatment dose does not inhibit breathing, long-term use without addiction and tolerance In 1956, it was listed as an over-the-counter drug by the U.S FDA and honored as "the safest central antitussive drug in modern times"; in 1961, it was designated as a non narcotic drug at the world narcotics Conference; in 1989, the World Health Organization considered "dextromethorphan is a antitussive drug replacing codeine" Drug users range from children to the elderly Dextromethorphan is one of the four antitussive drugs without compound expectorant in the medical insurance catalogue of 2019 According to the database of chemical terminal competition pattern of China's urban public hospitals on minenet, dextromethorphan's sales in 2018 ranked first among the antitussive drugs without compound expectorant in the medical insurance catalogue of 2019 According to the sales Mining System of pharmaceutical intelligence data hospital, South China Pharmaceutical still occupies the majority of the market share among the sales enterprises of Dextromethorphan Hydrobromide tablets According to the announcement, Zhongsheng Pharmaceutical Co., Ltd has carried out more than ten varieties of conformity assessment In addition to metformin hydrochloride tablets, isoniazid tablets, cefradine capsules and dextromethorphan hydrobromide tablets that have passed the conformity assessment of generic drugs, six varieties of ethylambutol hydrochloride tablets, ribavirin tablets and gliclazide tablets have been accepted by the CDE of conformity assessment of generic drugs and are under review and approval Adorable adorable